Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Peptide therapy stories

Oct 28, 2026

HHS allows temporary compounding of six unapproved peptides

The Department of Health and Human Services announced a policy permitting compounding pharmacies to temporarily produce six peptides that have not yet been approved by FDA, advancing access to controversial wellness compounds while permanent regulations are developed.

Oct 28, 2026·5 sources
00
Jul 24, 2026

FDA Advisory Panel Recommends Easing Restrictions on Unapproved Peptides Despite Agency Scientists' Concerns

Outside advisers to the U.S. Food and Drug Administration narrowly voted to recommend broader access to several unapproved peptides popular in wellness circles, backing a push by HHS Secretary Robert F. Kennedy Jr. despite objections from FDA career scientists about limited safety data and potential conflicts of interest among panelists.

Jul 24, 2026·8 sources
00
Jul 22, 2026

FDA panel votes to allow compounding of peptide BPC-157

FDA advisory panel voted to place peptide BPC-157 on a list allowing broader pharmacy compounding, the first of seven peptides under review. The decision supports HHS Secretary RFK Jr.'s push to expand access to these compounds.

Jul 22, 2026·6 sources
00

Top claims

  • ▪The Department of Health and Human Services stated its enforcement discretion policy aims to discourage the widespread use of research-use-only peptides supplied by foreign manufacturers that present safety risks to U.S. patients
  • ▪In July 2026, a majority of external advisers on the Food and Drug Administration's Pharmacy Compounding Advisory Committee voted in favor of expanding availability for six peptides, despite agency staff findings of insufficient safety and efficacy evidence
  • ▪The Department of Health and Human Services limited enforcement discretion to temporarily allow compounding pharmacies, federal facilities, and licensed physicians to manufacture and sell six unapproved peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax

People involved

Robert F. Kennedy Jr.

Subtopics

Biohacking & optimization1BPC-1571Compounding pharmacies1Epithalon1FDA regulation1FDA regulatory process1Government and Regulatory Policy1MOTS-c1Peptide regulation1Peptide Therapy Safety1Peptides & Emerging Supplement Trends1Public healthcare1Supplement regulation1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories